Daina Graybosch
Stock Analyst at Leerink Partners
(0.86)
# 3,718
Out of 4,854 analysts
107
Total ratings
36.36%
Success rate
-11.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Downgrades: Market Perform | $47 → $9 | $10.17 | -11.50% | 8 | May 14, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $78.97 | +50.69% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.32 | +51.52% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.32 | +209.60% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $68.15 | -42.77% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $0.67 | +350.45% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.62 | +2,171.62% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.60 | +525.00% | 7 | Jan 6, 2023 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $2.18 | +312.84% | 10 | Nov 15, 2022 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $40 → $38 | $9.97 | +281.14% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.80 | +110.57% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $108.49 | +106.47% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.90 | +1,478.95% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.42 | +1,097.18% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.74 | +417.24% | 4 | Feb 25, 2022 |
iTeos Therapeutics
May 14, 2025
Downgrades: Market Perform
Price Target: $47 → $9
Current: $10.17
Upside: -11.50%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $78.97
Upside: +50.69%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.32
Upside: +51.52%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.32
Upside: +209.60%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $68.15
Upside: -42.77%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $0.67
Upside: +350.45%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.62
Upside: +2,171.62%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.60
Upside: +525.00%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.18
Upside: +312.84%
Arcus Biosciences
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $9.97
Upside: +281.14%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.80
Upside: +110.57%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $108.49
Upside: +106.47%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.90
Upside: +1,478.95%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.42
Upside: +1,097.18%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.74
Upside: +417.24%